title: Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.
abstract: Since the establishment of extraovarian peritoneal serous papillary carcinoma (EPSPC) as a clinical entity in 1959, less than 250 cases have been described and its clinicopathologic features remain obscure. The present series is a retrospective, case-controlled study comparing the response and survival to cytoreductive surgery followed by cisplatin-based multiagent chemotherapy of 33 women with confirmed EPSPC versus 33 cases with papillary serous ovarian cancer (PSOC). Each EPSPC case was matched to a PSOC control for extent and distribution of disease prior to and following cytoreductive surgery, tumor grade, patient age, and treatment. Additionally, the new Gynecologic Oncology Group criteria for the diagnosis for EPSPC are discussed. There were no significant differences in tumor response to therapy, disease-free interval, and actuarial survival between cases and controls. These data suggest that EPSPC is clinically similar to PSOC and support the need for a prospective clinical trial to compare these two entities further.
authors.affiliation: Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange 92668.
authors.forename: J D
authors.initials: JD
authors.lastname: Bloss
authors.forename: S Y
authors.initials: SY
authors.lastname: Liao
authors.forename: R E
authors.initials: RE
authors.lastname: Buller
authors.forename: A
authors.initials: A
authors.lastname: Manetta
authors.forename: M L
authors.initials: ML
authors.lastname: Berman
authors.forename: S
authors.initials: S
authors.lastname: McMeekin
authors.forename: L P
authors.initials: LP
authors.lastname: Bloss
authors.forename: P J
authors.initials: PJ
authors.lastname: DiSaia
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D012086:Reoperation; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin